Steven B. Bernitz

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA.

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA.